215453-91-1

Basic information

• Product Name: tert-butyl 7-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate
• CAS NO: 215453-91-1
• Molecular Weight: 263.337
• Mol File: 215453-91-1.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: tert-butyl 7-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 7-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate(215453-91-1)
• EPA Substance Registry System: tert-butyl 7-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate(215453-91-1)

Safety Data

• Hazardous Substances Data: 215453-91-1(Hazardous Substances Data)

Upstream product

• 188576-49-0 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid tert-butyl ester 
• 74-88-4 methyl iodide 
• 43207-78-9 7-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 24608-52-4 tert-butyl chloroformate 
• 22246-04-4 7-methoxy-3,4-dihydro-2H-isoquinolin-1-one 
• 91247-71-1 2-4-methoxyphenylethylcarbamic acid methyl ester 
• 55-81-2 4-Methoxyphenethylamine 

Downstream Products

• 43207-78-9 7-methoxy-1,2,3,4-tetrahydroisoquinoline 
• 110192-19-3 7-hydroxy-1,2,3,4-tetrahydroisoquinoline hydrobromide 
• 1390656-08-2 7-(2,6-dichlorobenzyl)-5-[(7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-yl)amino]pyrido[3,4-d]pyridazin-4(3H)-one 

Relevant articles and documents

DDQ-promoted mild and efficient metal-free oxidative α-cyanation of N-acyl/sulfonyl 1,2,3,4-tetrahydroisoquinolines

A mild and highly efficient metal-free oxidative α-cyanation of N-acyl/sulfonyl 1,2,3,4-tetrahydroisoquinolines (THIQs) has been accomplished at an ambient temperature via DDQ oxidation and subsequent trapping of N-acyl/sulfonyl iminium ions with (n-Bu)s

BICYCLIC INHIBITORS OF ALK

The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

Bronchorelaxing compounds

A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts wherein A is CHR9, wherein R9 is H, C1-C6 alkyl; n is 1-3; B is CHR10, wherein R10 is H, C1-C6 alkyl; m is 1 or 2; D is O or S or optionally NR16, wherein R16 is H, C1-C6 alkyl or C2-C6 acyl; E is CR11R12 or NR13, wherein R11 and R12 are, independent of each other, H or C1-C6 alkyl, R13 is H or C1-C6 alkyl; F is C1-C18 alkyl which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction. Also disclosed are pharmaceutical compositions comprising the compound and methods for their manufacture.